- Home
- PRPH vs MYNZ Comparison
PRPH vs MYNZ Comparison
Compare PRPH & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- MYNZ
- Stock Information
- Founded
- PRPH 1989
- MYNZ 2021
- Country
- PRPH United States
- MYNZ Germany
- Employees
- PRPH N/A
- MYNZ N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- PRPH Health Care
- MYNZ Health Care
- Exchange
- PRPH Nasdaq
- MYNZ Nasdaq
- Market Cap
- PRPH 10.7M
- MYNZ 10.5M
- IPO Year
- PRPH 1997
- MYNZ 2021
- Fundamental
- Price
- PRPH $0.39
- MYNZ $3.44
- Analyst Decision
- PRPH
- MYNZ Buy
- Analyst Count
- PRPH 0
- MYNZ 3
- Target Price
- PRPH N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- PRPH 1.7M
- MYNZ 177.3K
- Earning Date
- PRPH 03-31-2025
- MYNZ 04-15-2025
- Dividend Yield
- PRPH N/A
- MYNZ N/A
- EPS Growth
- PRPH N/A
- MYNZ N/A
- EPS
- PRPH N/A
- MYNZ N/A
- Revenue
- PRPH $6,770,000.00
- MYNZ $893,991.00
- Revenue This Year
- PRPH N/A
- MYNZ $20.94
- Revenue Next Year
- PRPH $64.06
- MYNZ $18.01
- P/E Ratio
- PRPH N/A
- MYNZ N/A
- Revenue Growth
- PRPH N/A
- MYNZ N/A
- 52 Week Low
- PRPH $0.22
- MYNZ $0.18
- 52 Week High
- PRPH $7.48
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- PRPH 45.88
- MYNZ 37.70
- Support Level
- PRPH $0.35
- MYNZ $2.72
- Resistance Level
- PRPH $0.60
- MYNZ $5.34
- Average True Range (ATR)
- PRPH 0.08
- MYNZ 0.55
- MACD
- PRPH 0.00
- MYNZ -0.12
- Stochastic Oscillator
- PRPH 27.59
- MYNZ 27.48
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.